Francesca Mori
Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children’s University Hospital, Florence, Italy
Carlo Caffarelli
Clinica Pediatrica, Dipartimento di Medicina e Chirurgia, Azienda Ospedaliero-Universitaria, Università di Parma, Italy
Silvia Caimmi
Pediatric Clinic, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Paolo Bottau
Pediatric and Neonatology Unit, Imola Hospital, Imola (BO), Italy
Lucia Liotti
Department of Pediatrics, Senigallia Hospital, Senigallia, Italy
Fabrizio Franceschini
UOC Pediatria, Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, Italy
Fabio Cardinale
UOC di Pediatria, Azienda Ospedaliera-Universitaria “Consorziale-Policlinico”, Ospedale Pediatrico Giovanni XXIII, Bari, Italy
Roberto Bernardini
Pediatric Unit, “San Giuseppe” Hospital, Empoli, Italy
Giuseppe Crisafulli
UO Allergologia, Dipartimento di Pediatria, Università di Messina, Italy
Francesca Saretta
Pediatric Department, AAS2 Bassa Friulana-Isontina, Palmanova-Latisana, Italy; Pediatric Allergy Unit, Department of Medicine, Udine, Italy
Elio Novembre
Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children’s University Hospital, Florence, Italy
Keywords
children, drug reaction with eosinophilia and systemic symptoms, severe cutaneous adverse reactions
Abstract
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe reaction to drugs. Incidence of DRESS in children is not well known and the mortality rate seems to be lower than 10%. Anticonvulsants are the main drugs involved both in adults and in children. The treatment of choice is intravenous immunoglobulins and corticosteroids used in synergy. Today there are not controlled clinical trials regarding DRESS treatment in children. Anyway, the prompt withdrawn of the offending drug is of paramount importance for a better prognosis. DRESS sequels may occur, consequently, follow-up visits are required at least until the first year after the reaction.